DDInter1232 DDInter255
Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of the DNA double helix. Few other antibiotics have been discovered that work via this alkylating mechanism, making mitomycin relatively unique in the space of microbiota-derived therapies. Mitomycin's cross-linking activity has resulted in its approval for the treatment of a variety of cancers - the most recent of which is an April 2020 approval for its use in low-grade Upper Tract Urothelial Cancer (LG-UTUC) - as well as adjunctly to _ab externo_ glaucoma surgeries.
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Mitomycin {u} (Compound) upregulates {v} (Gene) MCOLN1
MCOLN1 {u} (Gene) is upregulated by {v} (Compound) Busulfan
Mitomycin {u} (Compound) downregulates {v} (Gene) PSRC1
PSRC1 {u} (Gene) is upregulated by {v} (Compound) Busulfan
Mitomycin {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Alkylating Activity {u} (Pharmacologic Class) includes {v} (Compound) Busulfan
Mitomycin {u} (Compound) downregulates {v} (Gene) MRPL19
MRPL19 {u} (Gene) is downregulated by {v} (Compound) Busulfan
Mitomycin {u} (Compound) upregulates {v} (Gene) DNAJB2
DNAJB2 {u} (Gene) is downregulated by {v} (Compound) Busulfan
Mitomycin {u} (Compound) causes {v} (Side Effect) Somnolence
Somnolence {u} (Side Effect) is caused by {v} (Compound) Busulfan
Mitomycin {u} (Compound) upregulates {v} (Gene) MCOLN1
MCOLN1 {u} (Gene) is regulated by {v} (Gene) PARP1
PARP1 {u} (Gene) is upregulated by {v} (Compound) Busulfan
Mitomycin {u} (Compound) downregulates {v} (Gene) PSRC1
PSRC1 {u} (Gene) regulates {v} (Gene) MAMLD1
MAMLD1 {u} (Gene) is upregulated by {v} (Compound) Busulfan
Mitomycin {u} (Compound) upregulates {v} (Gene) GPER1
GPER1 {u} (Gene) regulates {v} (Gene) MCOLN1
MCOLN1 {u} (Gene) is upregulated by {v} (Compound) Busulfan
Mitomycin {u} (Compound) upregulates {v} (Gene) TERT
TERT {u} (Gene) is associated with {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Busulfan
Mitomycin (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Busulfan (Compound)
Mitomycin (Compound) downregulates PSRC1 (Gene) and PSRC1 (Gene) is upregulated by Busulfan (Compound)
Mitomycin (Compound) is included by Alkylating Activity (Pharmacologic Class) and Alkylating Activity (Pharmacologic Class) includes Busulfan (Compound)
Mitomycin (Compound) downregulates MRPL19 (Gene) and MRPL19 (Gene) is downregulated by Busulfan (Compound)
Mitomycin (Compound) upregulates DNAJB2 (Gene) and DNAJB2 (Gene) is downregulated by Busulfan (Compound)
Mitomycin (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Busulfan (Compound)
Mitomycin (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is regulated by PARP1 (Gene) and PARP1 (Gene) is upregulated by Busulfan (Compound)
Mitomycin (Compound) downregulates PSRC1 (Gene) and PSRC1 (Gene) regulates MAMLD1 (Gene) and MAMLD1 (Gene) is upregulated by Busulfan (Compound)
Mitomycin (Compound) upregulates GPER1 (Gene) and GPER1 (Gene) regulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Busulfan (Compound)
Mitomycin (Compound) upregulates TERT (Gene) and TERT (Gene) is associated with hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Busulfan (Compound)